Should you buy Molina Healthcare (MOH)?
Updated
Molina Healthcare carries a quality score below the minimum acceptable threshold, declining revenues, and an erratic earnings track record — compounded by heavy Medicaid and geographic concentration — making the current setup structurally weak with the stock already trading above its near-term target.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Approximately 75% of revenue is tied to the Medicaid program — a government-funded, government-regulated payer that exposes the company to legislative, reimbursement-rate, and enrollment-eligibility changes largely outside management's control. Bear case | If Medicaid concentration falls below 65% of total revenue, the business has meaningfully reduced its single-program dependency. | →Stable |
| CounterThe most recent quarter delivered a 23% positive earnings surprise, demonstrating that Medicaid operations can generate upside even under the current high-concentration structure. | ||
Reading the earnings record from most to least recent: the company posted a 23% beat in the latest quarter, but the three preceding quarters all missed — including a -921% miss — producing an average negative surprise of -238% and making forward earnings projections highly unreliable. Earnings | EPS surprise exceeds 5% for 2 consecutive quarters, establishing a new pattern of predictability. | →Stable |
| CounterThe most recent print broke the miss streak with a meaningful beat; if that reflects stabilized cost management, the historical miss pattern may not persist. | ||
Business quality has fallen below the minimum acceptable threshold, with revenue declining approximately 4% year-over-year, no identifiable competitive moat, and below-average returns on equity and assets — the core investment case lacks a structural driver of improvement. Warnings | Revenue growth turns positive for 2 consecutive quarters and quality metrics recover toward the minimum threshold. | →Stable |
| CounterFree cash flow conversion is exceptionally strong at over 400% of net income, suggesting the business generates meaningful cash despite soft headline quality metrics — this cash cushion could fund a recovery if conditions improve. | ||
Approximately 75% of revenue is tied to the Medicaid program — a government-funded, government-regulated payer that exposes the company to legislative, reimbursement-rate, and enrollment-eligibility changes largely outside management's control.
→Stable- Expectation
- If Medicaid concentration falls below 65% of total revenue, the business has meaningfully reduced its single-program dependency.
CounterThe most recent quarter delivered a 23% positive earnings surprise, demonstrating that Medicaid operations can generate upside even under the current high-concentration structure.
Reading the earnings record from most to least recent: the company posted a 23% beat in the latest quarter, but the three preceding quarters all missed — including a -921% miss — producing an average negative surprise of -238% and making forward earnings projections highly unreliable.
→Stable- Expectation
- EPS surprise exceeds 5% for 2 consecutive quarters, establishing a new pattern of predictability.
CounterThe most recent print broke the miss streak with a meaningful beat; if that reflects stabilized cost management, the historical miss pattern may not persist.
Business quality has fallen below the minimum acceptable threshold, with revenue declining approximately 4% year-over-year, no identifiable competitive moat, and below-average returns on equity and assets — the core investment case lacks a structural driver of improvement.
→Stable- Expectation
- Revenue growth turns positive for 2 consecutive quarters and quality metrics recover toward the minimum threshold.
CounterFree cash flow conversion is exceptionally strong at over 400% of net income, suggesting the business generates meaningful cash despite soft headline quality metrics — this cash cushion could fund a recovery if conditions improve.
▸ Show 1 more pillar▾ Show fewer
The stock is trading above its near-term price target with a reward-to-risk ratio of -0.07-to-1 — there is no upside buffer remaining at current prices, and the risk/reward geometry is unfavorable for new capital or for holding an existing position.
→Stable- Expectation
- A price correction of at least 10% below current levels, or a meaningful analyst target upgrade, would be required to restore a positive entry framework.
CounterIf the recent earnings beat signals a fundamental inflection, analysts may revise price targets upward to reflect improved forward estimates, re-establishing positive implied upside.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Approximately 75% of revenue is tied to the Medicaid program — a government-funded, government-regulated payer that exposes the company to legislative, reimbursement-rate, and enrollment-eligibility changes largely outside management's control.
Trip ifMedicaid revenue concentration falls below 60% of total revenue in any quarterly filing.
- P2Reading the earnings record from most to least recent: the company posted a 23% beat in the latest quarter, but the three preceding quarters all missed — including a -921% miss — producing an average negative surprise of -238% and making forward earnings projections highly unreliable.
Trip ifEPS surprise exceeds 5% for 2 consecutive quarters.
- P3Business quality has fallen below the minimum acceptable threshold, with revenue declining approximately 4% year-over-year, no identifiable competitive moat, and below-average returns on equity and assets — the core investment case lacks a structural driver of improvement.
Trip ifRevenue growth turns positive and exceeds 3% year-over-year for 2 consecutive quarters.
- P4The stock is trading above its near-term price target with a reward-to-risk ratio of -0.07-to-1 — there is no upside buffer remaining at current prices, and the risk/reward geometry is unfavorable for new capital or for holding an existing position.
Trip ifAnalyst consensus price target is revised upward by more than 15%, restoring positive upside above $232.
How the engine reached this verdict
TrendMatrix's engine output for Molina Healthcare Inc (MOH) is SELL_IF_HOLDING with high conviction, score 3.6/10 at $201.42. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold. Co-failing gates ( ASYMMETRY:-1.0=NEGATIVE) reinforce the read; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The engine's exit framework anchors to a tactical sell band near $201.42, with structural invalidation at $187.32. The asymmetric R:R against a reversal hypothesis is -0.04 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bear side: Concentration risk — Product: Medicaid (75.0%); Concentration risk — Customer: California, New York, Texas, Washington (54.0%); V8: Target reached (-14.3% upside). Active engine warnings: V8: Target reached (-14.3% upside), Quality below floor (3.0 < 4.0), V9 Gate Failed: ASYMMETRY:-1.0=NEGATIVE.
The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:5.1>=4.5.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates MOH — 10-dimension breakdown →
Bear case
- ▸Concentration risk — Product: Medicaid (75.0%)
- ▸Concentration risk — Customer: California, New York, Texas, Washington (54.0%)
- ▸V8: Target reached (-14.3% upside)